ATE284897T1 - Selfantigen-impfstoffe zur behandlung von b-zell lymphomen und sonstigen krebsen - Google Patents

Selfantigen-impfstoffe zur behandlung von b-zell lymphomen und sonstigen krebsen

Info

Publication number
ATE284897T1
ATE284897T1 AT00973516T AT00973516T ATE284897T1 AT E284897 T1 ATE284897 T1 AT E284897T1 AT 00973516 T AT00973516 T AT 00973516T AT 00973516 T AT00973516 T AT 00973516T AT E284897 T1 ATE284897 T1 AT E284897T1
Authority
AT
Austria
Prior art keywords
polypeptide
plant
lymphoma
tumor
produced
Prior art date
Application number
AT00973516T
Other languages
English (en)
Inventor
Stephen J Reinl
Thomas H Turpen
Alison A Mccormick
Daniel Tuse
John A Lindbo
Original Assignee
Large Scale Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Large Scale Biology Corp filed Critical Large Scale Biology Corp
Application granted granted Critical
Publication of ATE284897T1 publication Critical patent/ATE284897T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00973516T 2000-03-10 2000-10-13 Selfantigen-impfstoffe zur behandlung von b-zell lymphomen und sonstigen krebsen ATE284897T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52290000A 2000-03-10 2000-03-10
PCT/US2000/028362 WO2001068682A1 (en) 2000-03-10 2000-10-13 Self antigen vaccines for treating b cell lymphomas and other cancers

Publications (1)

Publication Number Publication Date
ATE284897T1 true ATE284897T1 (de) 2005-01-15

Family

ID=24082838

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00973516T ATE284897T1 (de) 2000-03-10 2000-10-13 Selfantigen-impfstoffe zur behandlung von b-zell lymphomen und sonstigen krebsen

Country Status (8)

Country Link
EP (1) EP1263779B1 (de)
JP (1) JP2003527399A (de)
AT (1) ATE284897T1 (de)
AU (2) AU2001212019B2 (de)
CA (1) CA2402086A1 (de)
DE (1) DE60016806T2 (de)
WO (1) WO2001068682A1 (de)
ZA (1) ZA200206798B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1571211B1 (de) * 2002-11-22 2010-01-20 Chugai Seiyaku Kabushiki Kaisha Antikörper gegen geschädigtes gewebe
US8008076B2 (en) 2004-04-27 2011-08-30 Chugai Seiyaku Kabushiki Kaisha Method of producing a nucleic acid encoding an antibody
US20100124741A1 (en) * 2008-11-18 2010-05-20 Quest Disgnostics Investments Incorporated METHODS FOR DETECTING IgH/BCL-1 CHROMOSOMAL TRANSLOCATION
CN107090459A (zh) 2011-07-12 2017-08-25 埃克斯生物科技公司 鉴定亲和力成熟的人类抗体

Also Published As

Publication number Publication date
EP1263779A1 (de) 2002-12-11
WO2001068682A1 (en) 2001-09-20
CA2402086A1 (en) 2001-09-20
AU2001212019B2 (en) 2006-12-14
AU1201901A (en) 2001-09-24
DE60016806T2 (de) 2005-12-15
DE60016806D1 (de) 2005-01-20
ZA200206798B (en) 2003-08-26
JP2003527399A (ja) 2003-09-16
EP1263779B1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
JPH04506662A (ja) 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
RU2324493C2 (ru) Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
EP0588578B1 (de) Zusammensetzung die sowohl eine lösliche als auch eine unlösliche Form eines Immunogens beinhaltet
DE3775458D1 (de) Vermehrung der antigenimmunogenizitaet.
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
DK182990D0 (da) T-celleepitoper og oligopeptider, deres anvendelse i immunogene konjugater og immunokonjugater samt vacciner indeholdende disse konjugater
ATE287947T1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
AU3847801A (en) Proteosome influenza vaccine
DK2181715T3 (da) Kunstige T-hjælpecelle-epitoper som immunstimulatorer for syntetiske peptidimmunogener
NO994983L (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
ATE317267T1 (de) Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
JP2004002463A (ja) インターロイキン含有安定ワクチン組成物
PT1033995E (pt) Celulas inteiras ou lisadas de insecto utilizadas como adjuvantes de antigenios
WO2001095919A3 (en) A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
EP1255554A4 (de) Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
Jahn-Schmid et al. Toward selective elicitation of TH1-controlled vaccination responses: vaccine applications of bacterial surface layer proteins
ATE284897T1 (de) Selfantigen-impfstoffe zur behandlung von b-zell lymphomen und sonstigen krebsen
IL92009A0 (en) Cell lines,monoclonal anti-bodies and pharmaceutical compositions containing the same
ATE72400T1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
ES2241122T3 (es) Formulaciones de inmunopotenciacion para uso como vacunas.
BR9306187A (pt) Vacina bacterin-toxóide pasteurella haemolytica tipo a-1
Chen et al. The investigation of DNA tetrahedral nanoparticles as mucosal vaccine carriers and adjuvants

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties